As diagnostic manufacturers expand the number of pathogens detected in a single test, the competitive battle is shifting towards assay design, integrated testing platforms, antimicrobial-resistance detection and the patents protecting these technologies.
The Race Is No Longer Just About Detecting More Pathogens
A patient with fever, respiratory symptoms or suspected sepsis may have several possible infections. Traditional testing can require separate assays, increasing laboratory workload and potentially delaying the identification of the cause. Multiplex molecular diagnostics addresses this challenge by detecting multiple pathogens from a single specimen within one testing workflow.
But the next competitive advantage is not simply a longer list of detectable pathogens. It is the ability to identify them reliably, distinguish clinically relevant results, detect selected antimicrobial-resistance markers and deliver results quickly without making testing prohibitively expensive or complicated.
This creates a technology and intellectual property (IP) contest across the entire diagnostic process, from sample preparation to the final result.
Why the Market Is Moving Beyond Respiratory Testing
Recent product developments show that manufacturers are expanding into gastrointestinal infections, bloodstream infections and resistance-marker detection.
| Development | Verified data | Why it matters |
| QIAGEN’s QIAstat-Dx BCID GPF Plus AMR Panel | FDA clearance announced on 10 August 2026; 20 pathogen targets and 10 antimicrobial-resistance markers; results in approximately one hour | Extends syndromic testing into bloodstream infections and combines pathogen identification with resistance-marker detection |
| Cepheid’s Xpert GI Panel | FDA clearance decision dated 16 January 2026 | Expands the GeneXpert platform into gastrointestinal pathogen testing |
| QIAGEN’s QIAstat-Dx Rise | Up to 160 tests per day, with batch processing of 16 samples | Shows how automation and throughput are becoming important alongside assay performance |
| WHO’s bacterial diagnostic landscape | The 2025 report examines available and pipeline tests for bacterial priority pathogens and resistance | Identifies unmet needs that manufacturers could address through new diagnostic technologies |
These developments point to a broader commercial strategy: build a platform once, then expand its value through additional assays, specimen types and clinical applications.
QIAGEN reported more than 5,200 cumulative QIAstat-Dx placements by the end of 2025, with the platform available in more than 100 countries. An established instrument base can help a company introduce additional panels to existing customers, although commercial success still depends on assay performance, demand, pricing and regulatory requirements.
Sources: QIAGEN’s official product announcements and FDA’s public clearance records are listed at the end.
The Clinical Problem Is Bigger Than Faster Testing
Antimicrobial resistance (AMR) makes the need for better diagnostics particularly urgent. When an infection is caused by a resistant bacterium, a treatment that would ordinarily work may be ineffective. Clinicians need timely information to support appropriate treatment decisions and antibiotic stewardship.
WHO’s 2024 Bacterial Priority Pathogens List identifies 24 pathogens across 15 families of antibiotic-resistant bacteria, categorised into critical, high and medium priority groups.
Yet the diagnostic pipeline still has important gaps. WHO’s October 2025 landscape analysis highlighted the lack of suitable multiplex platforms for identifying bloodstream infections directly from whole blood without culture in intermediate referral laboratories. It also identified limited access to simple point-of-care diagnostics and tests that help distinguish bacterial from viral infections.
These gaps matter commercially because a technology that works only in a sophisticated central laboratory may not address the needs of hospitals and healthcare facilities with limited infrastructure.
The opportunity is therefore not merely to increase the number of targets. It is to make reliable testing faster, more accessible and suitable for a wider range of clinical settings.
Five Technology Layers That Shape Patent Competition
Multiplex diagnostics depends on several interconnected technologies. A manufacturer may have a strong position in one layer while relying on third-party technologies elsewhere.
| Technology layer | What it does | Potential patent focus |
| Sample preparation | Releases and isolates genetic material from a specimen | Lysis, extraction chemistry, magnetic beads and inhibitor removal |
| Multiplex amplification | Amplifies several pathogen targets | Primer and probe combinations, reaction chemistry and cross-reactivity control |
| Signal detection | Distinguishes results from multiple targets | Fluorescent channels, melting curves, encoded particles and signal processing |
| Cartridge and fluidics | Integrates preparation, reactions and waste handling | Microfluidic channels, valves, chambers, reagent storage and contamination prevention |
| Interpretation and resistance detection | Converts analytical signals into usable results | Quality-control logic, resistance-marker combinations and result interpretation |
- Primer design and amplification
Multiplex PCR is more complex than combining several individual tests. Different primer sets can interact, compete for reagents or perform unevenly when pathogen concentrations vary. A panel must distinguish the intended targets while controlling cross-reactivity and maintaining appropriate analytical sensitivity.
Patent claims may cover specific primer and probe combinations, reaction conditions, amplification methods or techniques that improve performance across multiple targets.
The key question is whether the protection covers a particular assay or a broader technical method that competing developers would find difficult to avoid.
- Detection and cartridge design
Detecting more targets requires a reliable way to distinguish their signals. Fluorescent detection, melting-curve analysis and other multiplex architectures offer different approaches, each with technical trade-offs.
Integrated cartridges introduce another layer of competition. They can automate sample handling, reagent delivery, amplification and detection while reducing manual intervention. However, their engineering must control fluid movement, temperature, contamination and reagent stability.
Companies such as Cepheid, bioMérieux’s BioFire business and QIAGEN provide useful comparative cases because their commercial platforms integrate multiple steps into automated workflows.
Their product designs do not, by themselves, establish patent infringement or ownership of foundational technologies. That requires examination of the actual patent claims and relevant product features.
Which Companies Deserve Closer Patent Analysis?
| Manufacturer | Competitive focus | Priority for patent research |
| bioMérieux / BioFire | Integrated syndromic panels, including respiratory, gastrointestinal and pneumonia testing | Cartridge architecture, multiplex PCR, sample preparation and resistance-marker detection |
| Cepheid / Danaher | GeneXpert closed-cartridge molecular testing | Automated extraction, fluidics, thermal cycling and detection |
| QIAGEN | QIAstat-Dx sample-to-answer testing and expanding assay menu | Integrated workflows, assay chemistry, cartridges and resistance markers |
| Hologic | Panther Fusion and automated molecular testing | High-throughput processing, assay chemistry and flexible testing workflows |
| DiaSorin / Luminex | Multiplex molecular and alternative detection technologies | Signal encoding, detection chemistry and assay architecture |
| Seegene | Multiplex real-time PCR assay development | Primer and probe design, amplification performance and cross-reactivity management |
| Thermo Fisher Scientific | Molecular reagents, PCR chemistry and assay-development technologies | Polymerases, probes, reagent formulations and amplification methods |
This is a research shortlist, not a verified ranking of patent ownership or market share. Each company’s relevant portfolio must be established through patent records and product-specific evidence.
What a Meaningful Patent Landscape Must Measure
A simple count of published patents can be misleading. One invention may generate applications in several countries, while a large portfolio may contain expired rights, unrelated inventions or claims with little relevance to a commercial assay.
A defensible comparison should measure:
- Active patent families: unique inventions with relevant rights still in force in the jurisdictions studied.
- Claim relevance: whether independent claims cover a critical technical feature or merely mention multiplex testing.
- Product linkage: whether there is evidence connecting a patent to a particular instrument, cartridge or assay.
- Geographic coverage: protection in markets such as the United States, Europe, China, Japan and India.
- Remaining term: estimated patent expiry, taking account of applicable legal events and extensions.
- Licensing and disputes: publicly documented licences, ownership changes, litigation and settlements.
Patent-family counts should be normalised across subsidiaries and historical owners. Search strategies should combine terms such as “multiplex PCR”, “pathogen panel”, “integrated cartridge”, “nucleic-acid extraction” and “antimicrobial resistance marker” with relevant patent classifications.
The resulting analysis should identify which technology layers are concentrated among a small number of owners, where alternative architectures may be available and which claims warrant closer legal review.
Importantly, patent landscaping and freedom-to-operate analysis are different exercises. A landscape maps technological activity and ownership; freedom-to-operate analysis examines whether a proposed product or process may infringe enforceable claims in specific jurisdictions.
Where the Next Opportunities May Lie
Three areas deserve particular attention.
First, bloodstream-infection testing. Faster pathogen identification and resistance-marker detection could address a significant clinical need. However, direct-from-blood testing remains technically challenging, and a positive blood-culture workflow should not be confused with direct detection from whole blood.
Second, higher multiplexing without higher complexity. Better primer design, signal discrimination and integrated sample preparation could enable broader panels without proportionately increasing instrument cost or workflow difficulty.
Third, decentralised testing. Smaller, robust and easy-to-use systems could address gaps in facilities that cannot support sophisticated central laboratory infrastructure. This will require attention to sample preparation, reagent stability, usability, cost and performance across specimen types.
These are promising areas for investigation, not confirmed patent white spaces. Establishing a genuine opportunity requires prior-art searches and analysis of relevant claims.
Who Controls the Future?
No single patent count or product announcement can establish which manufacturer controls multiplex infectious disease testing. The competitive advantage comes from the combination of technically defensible inventions, reliable assays, regulatory evidence, manufacturing capability and an installed platform that can support additional tests.
The companies best positioned to compete will be those that can expand pathogen coverage while maintaining reliable performance, simplify workflows and deliver clinically useful results across different healthcare settings.
For IP teams, the priority is to identify the claims that protect genuine technological differentiation, evaluate third-party rights and monitor competitor filings across the entire diagnostic workflow.
The decisive question is not who can detect the most pathogens. It is who can make multiplex testing reliable, scalable and commercially sustainable while protecting the technologies that enable it.
SOURCES:
- https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Receives-U-S–FDA-Clearance-for-First-QIAstat-Dx-Bloodstream-Infection-Panel/default.aspx
- https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Receives-U-S–Clearance-for-Gastrointestinal-Panels-on-Fully-Automated-QIAstat-Dx-Rise-Syndromic-Testing-System/default.aspx
- https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2025/QIAGEN-Gains-U-S–Clearance-of-Higher-Throughput-QIAstat-Dx-Rise-Expanding-Patient-Access-to-Rapid-Syndromic-Testing/default.aspx
- https://www.who.int/publications/i/item/9789240109827
- https://www.who.int/publications/i/item/9789240093461
- https://www.who.int/vanuatu/news/detail-global/02-10-2025-who-releases-new-reports-on-new-tests-and-treatments-in-development-for-bacterial-infections
- https://www.patsnap.com/resources/blog/rd-blog/multiplex-pcr-primer-design-for-pathogen-panel-testing-patent-landscape-patent-landscape/
- https://www.patsnap.com/resources/blog/rd-blog/multiplex-melting-curve-analysis-for-pathogen-identification-patent-landscape-patent-landscape/
- https://www.patsnap.com/resources/blog/rd-blog/molecular-diagnostics-platforms-patent-landscape/
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://www.grandviewresearch.com/industry-analysis/multiplex-pcr-panel-testing-market-report
- https://www.grandviewresearch.com/industry-analysis/us-infectious-respiratory-disease-diagnostics-market-report
